<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2020v4.2">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2022-06-02T08:25:43-05:00</ReturnTs>
    <TaxPeriodEndDt>2021-09-30</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>440160260</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>FORVIS LLP</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>500 RIDGEFIELD COURT</AddressLine1Txt>
        <CityNm>ASHEVILLE</CityNm>
        <StateAbbreviationCd>NC</StateAbbreviationCd>
        <ZIPCd>28806</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2020-10-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>581966822</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>PEDIATRIC BRAIN TUMOR FOUNDATION</BusinessNameLine1Txt>
        <BusinessNameLine2Txt>OF THE UNITED STATES INC</BusinessNameLine2Txt>
      </BusinessName>
      <BusinessNameControlTxt>PEDI</BusinessNameControlTxt>
      <PhoneNum>8286656891</PhoneNum>
      <USAddress>
        <AddressLine1Txt>6065 ROSWELL ROAD NE STE 505</AddressLine1Txt>
        <CityNm>ATLANTA</CityNm>
        <StateAbbreviationCd>GA</StateAbbreviationCd>
        <ZIPCd>30328</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>ANNE SUTTON</PersonNm>
      <PersonTitleTxt>SECRETARY</PersonTitleTxt>
      <PhoneNum>8286656891</PhoneNum>
      <SignatureDt>2022-06-02</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>ANNE</PersonFirstNm>
        <PersonLastNm>SUTTON</PersonLastNm>
      </PersonFullName>
      <SSN>999009999</SSN>
    </SigningOfficerGrp>
    <PreparerPersonGrp>
      <PreparerPersonNm>AMY BIBBY</PreparerPersonNm>
      <PTIN>P00445891</PTIN>
      <PhoneNum>8282542254</PhoneNum>
      <PreparationDt>2022-06-02</PreparationDt>
    </PreparerPersonGrp>
    <AdditionalFilerInformation>
      <TrustedCustomerGrp>
        <TrustedCustomerCd>3</TrustedCustomerCd>
        <AuthenticationAssuranceLevelCd>AAL1</AuthenticationAssuranceLevelCd>
        <IdentityAssuranceLevelCd>IAL1</IdentityAssuranceLevelCd>
      </TrustedCustomerGrp>
    </AdditionalFilerInformation>
    <TaxYr>2020</TaxYr>
    <BuildTS>2022-09-23 18:48:47Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="9">
    <IRS990 documentId="RetDoc1038000001" referenceDocumentId="RetDoc1044400001">
      <PrincipalOfficerNm>COURTNEY DAVIES</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>6065 ROSWELL ROAD NE STE 505</AddressLine1Txt>
        <CityNm>ATLANTA</CityNm>
        <StateAbbreviationCd>GA</StateAbbreviationCd>
        <ZIPCd>30328</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>6017204</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>0</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>WWW.CURETHEKIDS.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>1992</FormationYr>
      <LegalDomicileStateCd>GA</LegalDomicileStateCd>
      <ActivityOrMissionDesc>ELIMINATE CHILDHOOD BRAIN TUMORS AND SUPPORT FAMILIES LIVING WITH THIS DEVASTATING DISEASE.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>12</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>12</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>38</TotalEmployeeCnt>
      <TotalVolunteersCnt>350</TotalVolunteersCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>0</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>3836629</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>6015457</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>0</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>14534</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>-15461</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>0</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>0</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>3851163</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>5999996</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>1992418</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>2128614</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>1865638</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>1907400</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>0</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>717603</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>769584</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>1231795</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>4627640</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>5267809</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>-776477</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>732187</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>5248201</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>6277731</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>549498</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>846841</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>4698703</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>5430890</NetAssetsOrFundBalancesEOYAmt>
      <MissionDesc>VISION: A WORLD WITHOUT CHILDHOOD BRAIN TUMORS.MISSION: CARE. CURE. THRIVE.</MissionDesc>
      <SignificantNewProgramSrvcInd>0</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>0</SignificantChangeInd>
      <ExpenseAmt>3966715</ExpenseAmt>
      <GrantAmt>2128614</GrantAmt>
      <RevenueAmt>5999996</RevenueAmt>
      <Desc>SEE SCHEDULE O</Desc>
      <TotalProgramServiceExpensesAmt>3966715</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="RetDoc1039100001">1</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="RetDoc1234500001">1</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd referenceDocumentId="RetDoc1039600001">0</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd referenceDocumentId="RetDoc1039600001">0</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd referenceDocumentId="RetDoc1039600001">0</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd referenceDocumentId="RetDoc1040000001">0</DonorAdvisedFundInd>
      <ConservationEasementsInd referenceDocumentId="RetDoc1040000001">0</ConservationEasementsInd>
      <CollectionsOfArtInd referenceDocumentId="RetDoc1040000001">0</CollectionsOfArtInd>
      <CreditCounselingInd referenceDocumentId="RetDoc1040000001">0</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd>1</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="RetDoc1040000001">1</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="RetDoc1040000001">0</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd referenceDocumentId="RetDoc1040000001">0</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="RetDoc1040000001">0</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="RetDoc1040000001">0</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="RetDoc1040000001">1</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">1</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">0</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>0</SchoolOperatingInd>
      <ForeignOfficeInd>0</ForeignOfficeInd>
      <ForeignActivitiesInd>0</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd>0</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd>0</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd>0</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd>0</FundraisingActivitiesInd>
      <GamingActivitiesInd>0</GamingActivitiesInd>
      <OperateHospitalInd>0</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="RetDoc1041900001">1</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="RetDoc1041900001">1</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="RetDoc1042400001">1</ScheduleJRequiredInd>
      <TaxExemptBondsInd>0</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd>0</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>0</PYExcessBenefitTransInd>
      <LoanOutstandingInd>0</LoanOutstandingInd>
      <GrantToRelatedPersonInd>0</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>0</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>0</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>0</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd referenceDocumentId="RetDoc1042900001">1</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd referenceDocumentId="RetDoc1042900001">0</DeductibleArtContributionInd>
      <TerminateOperationsInd>0</TerminateOperationsInd>
      <PartialLiquidationInd>0</PartialLiquidationInd>
      <DisregardedEntityInd>0</DisregardedEntityInd>
      <RelatedEntityInd>0</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>0</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd>0</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd>0</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>1</ScheduleORequiredInd>
      <IRPDocumentCnt>25</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <BackupWthldComplianceInd>1</BackupWthldComplianceInd>
      <EmployeeCnt>38</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>1</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>0</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>0</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>0</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>1</QuidProQuoContributionsInd>
      <QuidProQuoContriDisclInd>1</QuidProQuoContriDisclInd>
      <Form8282PropertyDisposedOfInd>0</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
      <IndoorTanningServicesInd>0</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>0</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>12</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>12</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>0</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>0</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>0</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>0</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>0</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>0</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>0</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>1</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>1</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>0</OfficerMailingAddressInd>
      <LocalChaptersInd>1</LocalChaptersInd>
      <PoliciesReferenceChaptersInd>1</PoliciesReferenceChaptersInd>
      <Form990ProvidedToGvrnBodyInd>1</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>1</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>1</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>1</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>1</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>1</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>1</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>1</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>0</InvestmentInJointVentureInd>
      <StatesWhereCopyOfReturnIsFldCd>AL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AZ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>FL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>GA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>LA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ME</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MD</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NJ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NM</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ND</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>PA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>RI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>SC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WV</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CO</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>TN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>UT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>HI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MO</StatesWhereCopyOfReturnIsFldCd>
      <OwnWebsiteInd>X</OwnWebsiteInd>
      <OtherWebsiteInd>X</OtherWebsiteInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <PersonNm>GEOFF STILL</PersonNm>
        <PhoneNum>8284180814</PhoneNum>
        <USAddress>
          <AddressLine1Txt>6065 ROSWELL ROAD NE STE 505</AddressLine1Txt>
          <CityNm>ATLANTA</CityNm>
          <StateAbbreviationCd>GA</StateAbbreviationCd>
          <ZIPCd>30328</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <PersonNm>ANDREW AJ JANOWER</PersonNm>
        <TitleTxt>CHAIR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KRISTIN YOUNG</PersonNm>
        <TitleTxt>VICE CHAIR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ANNE SUTTON</PersonNm>
        <TitleTxt>SECRETARY</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JEFF GELFAND</PersonNm>
        <TitleTxt>TREASURER</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>DOUG PORTER</PersonNm>
        <TitleTxt>CHAIRMAN EMERITUS</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>CHUCK BODERMAN</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>CHASE JONES</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LARRY LITTLE</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KARL MUELLER</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KEN MURPHY</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JOHN RAGNONI</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SUSIE ROSSICK</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JILL SCOGNAMIGLIO</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>COURTNEY DAVIES</PersonNm>
        <TitleTxt>PRESIDENT/CEO</TitleTxt>
        <AverageHoursPerWeekRt>50.00</AverageHoursPerWeekRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>275380</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>GEOFF STILL</PersonNm>
        <TitleTxt>CFO</TitleTxt>
        <AverageHoursPerWeekRt>50.00</AverageHoursPerWeekRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>132887</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>13892</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>408267</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>13892</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>2</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>0</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>1</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>0</CompensationFromOtherSrcsInd>
      <CntrctRcvdGreaterThan100KCnt>0</CntrctRcvdGreaterThan100KCnt>
      <AllOtherContributionsAmt>6015457</AllOtherContributionsAmt>
      <NoncashContributionsAmt>113725</NoncashContributionsAmt>
      <TotalContributionsAmt>6015457</TotalContributionsAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>1747</TotalRevenueColumnAmt>
        <ExclusionAmt>1747</ExclusionAmt>
      </InvestmentIncomeGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <OtherAmt>17208</OtherAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <OtherAmt>-17208</OtherAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>-17208</TotalRevenueColumnAmt>
        <ExclusionAmt>-17208</ExclusionAmt>
      </NetGainOrLossInvestmentsGrp>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>5999996</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>-15461</ExclusionAmt>
      </TotalRevenueGrp>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>1668820</TotalAmt>
        <ProgramServicesAmt>1668820</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <GrantsToDomesticIndividualsGrp>
        <TotalAmt>459794</TotalAmt>
        <ProgramServicesAmt>459794</ProgramServicesAmt>
      </GrantsToDomesticIndividualsGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>422159</TotalAmt>
        <ProgramServicesAmt>223940</ProgramServicesAmt>
        <ManagementAndGeneralAmt>143143</ManagementAndGeneralAmt>
        <FundraisingAmt>55076</FundraisingAmt>
      </CompCurrentOfcrDirectorsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>1159437</TotalAmt>
        <ProgramServicesAmt>790259</ProgramServicesAmt>
        <ManagementAndGeneralAmt>152860</ManagementAndGeneralAmt>
        <FundraisingAmt>216318</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <PensionPlanContributionsGrp>
        <TotalAmt>39738</TotalAmt>
        <ProgramServicesAmt>26168</ProgramServicesAmt>
        <ManagementAndGeneralAmt>8335</ManagementAndGeneralAmt>
        <FundraisingAmt>5235</FundraisingAmt>
      </PensionPlanContributionsGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>199070</TotalAmt>
        <ProgramServicesAmt>105213</ProgramServicesAmt>
        <ManagementAndGeneralAmt>47719</ManagementAndGeneralAmt>
        <FundraisingAmt>46138</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>86996</TotalAmt>
        <ProgramServicesAmt>57911</ProgramServicesAmt>
        <ManagementAndGeneralAmt>16422</ManagementAndGeneralAmt>
        <FundraisingAmt>12663</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>417677</TotalAmt>
        <ProgramServicesAmt>219044</ProgramServicesAmt>
        <ManagementAndGeneralAmt>91132</ManagementAndGeneralAmt>
        <FundraisingAmt>107501</FundraisingAmt>
      </FeesForServicesOtherGrp>
      <AdvertisingGrp>
        <TotalAmt>43678</TotalAmt>
        <ProgramServicesAmt>38142</ProgramServicesAmt>
        <FundraisingAmt>5536</FundraisingAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>114268</TotalAmt>
        <ProgramServicesAmt>63243</ProgramServicesAmt>
        <ManagementAndGeneralAmt>13276</ManagementAndGeneralAmt>
        <FundraisingAmt>37749</FundraisingAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>15410</TotalAmt>
        <ProgramServicesAmt>13037</ProgramServicesAmt>
        <ManagementAndGeneralAmt>2373</ManagementAndGeneralAmt>
      </InformationTechnologyGrp>
      <OccupancyGrp>
        <TotalAmt>224945</TotalAmt>
        <ProgramServicesAmt>184068</ProgramServicesAmt>
        <ManagementAndGeneralAmt>36411</ManagementAndGeneralAmt>
        <FundraisingAmt>4466</FundraisingAmt>
      </OccupancyGrp>
      <TravelGrp>
        <TotalAmt>7698</TotalAmt>
        <ProgramServicesAmt>6014</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1684</ManagementAndGeneralAmt>
      </TravelGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>17269</TotalAmt>
        <ProgramServicesAmt>15719</ProgramServicesAmt>
        <FundraisingAmt>1550</FundraisingAmt>
      </ConferencesMeetingsGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>15797</TotalAmt>
        <ProgramServicesAmt>15000</ProgramServicesAmt>
        <ManagementAndGeneralAmt>797</ManagementAndGeneralAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>17158</TotalAmt>
        <ProgramServicesAmt>4260</ProgramServicesAmt>
        <ManagementAndGeneralAmt>12898</ManagementAndGeneralAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>FEES &amp; LICENSES</Desc>
        <TotalAmt>340758</TotalAmt>
        <ProgramServicesAmt>68906</ProgramServicesAmt>
        <ManagementAndGeneralAmt>46856</ManagementAndGeneralAmt>
        <FundraisingAmt>224996</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>MISCELLANEOUS</Desc>
        <TotalAmt>12146</TotalAmt>
        <ProgramServicesAmt>4599</ProgramServicesAmt>
        <ManagementAndGeneralAmt>7172</ManagementAndGeneralAmt>
        <FundraisingAmt>375</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>AUTO EXPENSE</Desc>
        <TotalAmt>4062</TotalAmt>
        <ProgramServicesAmt>2578</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1484</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>REPAIRS &amp; MAINTENANCE</Desc>
        <TotalAmt>929</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>929</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </OtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>5267809</TotalAmt>
        <ProgramServicesAmt>3966715</ProgramServicesAmt>
        <ManagementAndGeneralAmt>583491</ManagementAndGeneralAmt>
        <FundraisingAmt>717603</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <JointCostsInd>X</JointCostsInd>
      <CashNonInterestBearingGrp>
        <BOYAmt>1547950</BOYAmt>
        <EOYAmt>2257178</EOYAmt>
      </CashNonInterestBearingGrp>
      <AccountsReceivableGrp>
        <BOYAmt>202399</BOYAmt>
        <EOYAmt>519490</EOYAmt>
      </AccountsReceivableGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>33859</BOYAmt>
        <EOYAmt>27545</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>24894</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>13467</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>41066</BOYAmt>
        <EOYAmt>11427</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>3422927</BOYAmt>
        <EOYAmt>3462091</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <TotalAssetsGrp>
        <BOYAmt>5248201</BOYAmt>
        <EOYAmt>6277731</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>238563</BOYAmt>
        <EOYAmt>74542</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <GrantsPayableGrp>
        <BOYAmt>310935</BOYAmt>
        <EOYAmt>772299</EOYAmt>
      </GrantsPayableGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>549498</BOYAmt>
        <EOYAmt>846841</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>1392732</BOYAmt>
        <EOYAmt>2078046</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <DonorRestrictionNetAssetsGrp>
        <BOYAmt>3305971</BOYAmt>
        <EOYAmt>3352844</EOYAmt>
      </DonorRestrictionNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>4698703</BOYAmt>
        <EOYAmt>5430890</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>5248201</BOYAmt>
        <EOYAmt>6277731</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <ReconcilationRevenueExpnssAmt>732187</ReconcilationRevenueExpnssAmt>
      <OtherChangesInNetAssetsAmt>0</OtherChangesInNetAssetsAmt>
      <InfoInScheduleOPartXIIInd>X</InfoInScheduleOPartXIIInd>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>0</AccountantCompileOrReviewInd>
      <FSAuditedInd>1</FSAuditedInd>
      <FSAuditedBasisGrp>
        <SeparateBasisFinclStmtInd>X</SeparateBasisFinclStmtInd>
      </FSAuditedBasisGrp>
      <AuditCommitteeInd>1</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>0</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="RetDoc1039100001">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>6347569</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>5643146</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>9927494</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>6471860</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>3836629</CurrentTaxYearAmt>
        <TotalAmt>32226698</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>6347569</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>5643146</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>9927494</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>6471860</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>3836629</CurrentTaxYearAmt>
        <TotalAmt>32226698</TotalAmt>
      </TotalCalendarYear170Grp>
      <SubstantialContributorsTotAmt>1395890</SubstantialContributorsTotAmt>
      <PublicSupportTotal170Amt>30830808</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>77585</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>109546</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>16620</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>45248</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>14534</CurrentTaxYearAmt>
        <TotalAmt>263533</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <TotalSupportAmt>32490231</TotalSupportAmt>
      <PublicSupportCY170Pct>0.94890</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.94250</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
      <Form990ScheduleAPartVIGrp>
        <FormAndLineReferenceDesc>SCHEDULE A PART VI</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION CHANGED THEIR YEAR END DATE TO 9/30.</ExplanationTxt>
      </Form990ScheduleAPartVIGrp>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleC documentId="RetDoc1039600001">
      <OtherExemptPurposeExpendGrp>
        <FilingOrganizationsTotalAmt>5267809</FilingOrganizationsTotalAmt>
      </OtherExemptPurposeExpendGrp>
      <TotalExemptPurposeExpendGrp>
        <FilingOrganizationsTotalAmt>5267809</FilingOrganizationsTotalAmt>
      </TotalExemptPurposeExpendGrp>
      <LobbyingNontaxableAmountGrp>
        <FilingOrganizationsTotalAmt>413390</FilingOrganizationsTotalAmt>
      </LobbyingNontaxableAmountGrp>
      <GrassrootsNontaxableGrp>
        <FilingOrganizationsTotalAmt>103348</FilingOrganizationsTotalAmt>
      </GrassrootsNontaxableGrp>
      <TotLbbyngGrassrootMnsNonTxGrp>
        <FilingOrganizationsTotalAmt>0</FilingOrganizationsTotalAmt>
      </TotLbbyngGrassrootMnsNonTxGrp>
      <TotLbbyExpendMnsLbbyngNonTxGrp>
        <FilingOrganizationsTotalAmt>0</FilingOrganizationsTotalAmt>
      </TotLbbyExpendMnsLbbyngNonTxGrp>
      <AvgLobbyingNontaxableAmountGrp>
        <CurrentYearMinus3Amt>449288</CurrentYearMinus3Amt>
        <CurrentYearMinus2Amt>404647</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>506409</CurrentYearMinus1Amt>
        <CurrentYearAmt>413390</CurrentYearAmt>
        <TotalAmt>1773734</TotalAmt>
      </AvgLobbyingNontaxableAmountGrp>
      <LobbyingCeilingAmt>2660601</LobbyingCeilingAmt>
      <AvgGrassrootsNontaxableGrp>
        <CurrentYearMinus3Amt>112322</CurrentYearMinus3Amt>
        <CurrentYearMinus2Amt>101162</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>126602</CurrentYearMinus1Amt>
        <CurrentYearAmt>103348</CurrentYearAmt>
        <TotalAmt>443434</TotalAmt>
      </AvgGrassrootsNontaxableGrp>
      <GrassrootsCeilingAmt>665151</GrassrootsCeilingAmt>
    </IRS990ScheduleC>
    <IRS990ScheduleD documentId="RetDoc1040000001">
      <CYEndwmtFundGrp>
        <BeginningYearBalanceAmt>816243</BeginningYearBalanceAmt>
        <ContributionsAmt>225703</ContributionsAmt>
        <EndYearBalanceAmt>1041946</EndYearBalanceAmt>
      </CYEndwmtFundGrp>
      <CYMinus1YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>1016243</BeginningYearBalanceAmt>
        <OtherExpendituresAmt>200000</OtherExpendituresAmt>
        <EndYearBalanceAmt>816243</EndYearBalanceAmt>
      </CYMinus1YrEndwmtFundGrp>
      <CYMinus2YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>1016243</BeginningYearBalanceAmt>
        <EndYearBalanceAmt>1016243</EndYearBalanceAmt>
      </CYMinus2YrEndwmtFundGrp>
      <CYMinus3YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>1716243</BeginningYearBalanceAmt>
        <OtherExpendituresAmt>700000</OtherExpendituresAmt>
        <EndYearBalanceAmt>1016243</EndYearBalanceAmt>
      </CYMinus3YrEndwmtFundGrp>
      <CYMinus4YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>1716243</BeginningYearBalanceAmt>
        <EndYearBalanceAmt>1716243</EndYearBalanceAmt>
      </CYMinus4YrEndwmtFundGrp>
      <BoardDesignatedBalanceEOYPct>1.00000</BoardDesignatedBalanceEOYPct>
      <EndowmentsHeldUnrelatedOrgInd>0</EndowmentsHeldUnrelatedOrgInd>
      <EndowmentsHeldRelatedOrgInd>0</EndowmentsHeldRelatedOrgInd>
      <EquipmentGrp>
        <OtherCostOrOtherBasisAmt>24894</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>13467</DepreciationAmt>
        <BookValueAmt>11427</BookValueAmt>
      </EquipmentGrp>
      <TotalBookValueLandBuildingsAmt>11427</TotalBookValueLandBuildingsAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <TotalRevEtcAuditedFinclStmtAmt>6016604</TotalRevEtcAuditedFinclStmtAmt>
      <OtherRevenueAmt>17208</OtherRevenueAmt>
      <RevenueNotReportedAmt>17208</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>5999396</RevenueSubtotalAmt>
      <InvestmentExpensesNotIncldAmt>600</InvestmentExpensesNotIncldAmt>
      <RevenueNotReportedFinclStmtAmt>600</RevenueNotReportedFinclStmtAmt>
      <TotalRevenuePerForm990Amt>5999996</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>5284417</TotExpnsEtcAuditedFinclStmtAmt>
      <OtherExpensesIncludedAmt>17208</OtherExpensesIncludedAmt>
      <ExpensesNotReportedAmt>17208</ExpensesNotReportedAmt>
      <ExpensesSubtotalAmt>5267209</ExpensesSubtotalAmt>
      <InvestmentExpensesNotIncld2Amt>600</InvestmentExpensesNotIncld2Amt>
      <ExpensesNotRptFinclStmtAmt>600</ExpensesNotRptFinclStmtAmt>
      <TotalExpensesPerForm990Amt>5267809</TotalExpensesPerForm990Amt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART V, LINE 4:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ENDOWMENT FUNDS ARE A BOARD DESIGNATED RESERVE FUND TO ASSURE THE FOUNDATION'S ABILITY TO RESPOND TO PROGRAM RELATED OPPORTUNITIES (BOTH RESEARCH AND FAMILY SUPPORT) THAT MAY BE BEYOND THE FUNDS AVAILABLE FROM NORMAL OPERATIONS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART X, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF SEPTEMBER 30, 2021.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART XI, LINE 2D - OTHER ADJUSTMENTS:</FormAndLineReferenceDesc>
        <ExplanationTxt>LOSS ON SALE OF ASSETS 17,208.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART XII, LINE 2D - OTHER ADJUSTMENTS:</FormAndLineReferenceDesc>
        <ExplanationTxt>LOSS ON SALE OF ASSETS 17,208.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleI documentId="RetDoc1041900001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>DANA-FARBER CANCER INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>450 BROOKLINE AVE</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02215</ZIPCd>
        </USAddress>
        <RecipientEIN>422263040</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>190750</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH GRANTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>HEALTH RESEARCH ALLIANCE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 13605</AddressLine1Txt>
          <CityNm>RESEARCH TRIANGLE PARK</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>27709</ZIPCd>
        </USAddress>
        <RecipientEIN>680617198</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>112500</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>DUKE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 602651</AddressLine1Txt>
          <CityNm>CHARLOTTE</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>282602651</ZIPCd>
        </USAddress>
        <RecipientEIN>560532129</RecipientEIN>
        <IRCSectionDesc>GOVT</IRCSectionDesc>
        <CashGrantAmt>150000</CashGrantAmt>
        <PurposeOfGrantTxt>EARLY CAREER DEVELOPMENT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF CINCINNATI</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>2830 VICTORY PARKWAY</AddressLine1Txt>
          <CityNm>CINCINNATI</CityNm>
          <StateAbbreviationCd>OH</StateAbbreviationCd>
          <ZIPCd>45206</ZIPCd>
        </USAddress>
        <RecipientEIN>311779020</RecipientEIN>
        <IRCSectionDesc>GOVT</IRCSectionDesc>
        <CashGrantAmt>150000</CashGrantAmt>
        <PurposeOfGrantTxt>EARLY CAREER DEVELOPMENT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CHILDREN'S NATL MED CTRCHILDREN'S RSCH INST</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>111 MICHIGAN AVE NW</AddressLine1Txt>
          <CityNm>WASHINGTON</CityNm>
          <StateAbbreviationCd>DC</StateAbbreviationCd>
          <ZIPCd>20010</ZIPCd>
        </USAddress>
        <RecipientEIN>521640403</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>28593</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>WASHINGTON UNIVERSITY IN ST LOUIS</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1 BROOKINGS DR</AddressLine1Txt>
          <CityNm>ST LOUIS</CityNm>
          <StateAbbreviationCd>MO</StateAbbreviationCd>
          <ZIPCd>63130</ZIPCd>
        </USAddress>
        <RecipientEIN>431519670</RecipientEIN>
        <IRCSectionDesc>GOVT</IRCSectionDesc>
        <CashGrantAmt>100000</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>REGENTS OF UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>G395 WOLVERINE TOWER LOW RISE</AddressLine1Txt>
          <CityNm>ANN ARBOR</CityNm>
          <StateAbbreviationCd>MI</StateAbbreviationCd>
          <ZIPCd>481091279</ZIPCd>
        </USAddress>
        <RecipientEIN>386006309</RecipientEIN>
        <IRCSectionDesc>GOVT</IRCSectionDesc>
        <CashGrantAmt>70000</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH GRANTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>REGENTS OF UNIV CA SAN FRANCISCO</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1111 FRANKLIN ST 12TH FLOOR</AddressLine1Txt>
          <CityNm>OAKLAND</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94607</ZIPCd>
        </USAddress>
        <RecipientEIN>942829914</RecipientEIN>
        <IRCSectionDesc>GOVT</IRCSectionDesc>
        <CashGrantAmt>100000</CashGrantAmt>
        <PurposeOfGrantTxt>CLINICAL TRIAL</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>AMERICAN ASSOC FOR CANCER RESEARCH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>615 CHESTNUT ST 17TH FLOOR</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>191064404</ZIPCd>
        </USAddress>
        <RecipientEIN>236251648</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>90000</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>SYDNEY'S INCREDIBLE DEFEAT OF EWING'S SARCOMA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1655 N COMMERCE PKWY SUITE 102</AddressLine1Txt>
          <CityNm>WESTON</CityNm>
          <StateAbbreviationCd>FL</StateAbbreviationCd>
          <ZIPCd>33326</ZIPCd>
        </USAddress>
        <RecipientEIN>453368209</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>89908</CashGrantAmt>
        <PurposeOfGrantTxt>OPPORTUNITY GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CHILDREN'S HEALTHCARE OF ATLANTA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1600 TULLIE CIRCLE</AddressLine1Txt>
          <CityNm>ATLANTA</CityNm>
          <StateAbbreviationCd>GA</StateAbbreviationCd>
          <ZIPCd>30329</ZIPCd>
        </USAddress>
        <RecipientEIN>582367819</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>5073</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>AKRON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>214 W BOWERY ST</AddressLine1Txt>
          <CityNm>AKRON</CityNm>
          <StateAbbreviationCd>OH</StateAbbreviationCd>
          <ZIPCd>44308</ZIPCd>
        </USAddress>
        <RecipientEIN>340714357</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>5013</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>BRENNER CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>MEDICAL CENTER BLVD</AddressLine1Txt>
          <CityNm>WINSTONSALEM</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>27157</ZIPCd>
        </USAddress>
        <RecipientEIN>510190238</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>18569</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>EAST TENNESSEE CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>2018 W CLINCH AVE</AddressLine1Txt>
          <CityNm>KNOXVILLE</CityNm>
          <StateAbbreviationCd>TN</StateAbbreviationCd>
          <ZIPCd>37916</ZIPCd>
        </USAddress>
        <RecipientEIN>626002604</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>14632</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>HASBRO CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>593 EDDY ST</AddressLine1Txt>
          <CityNm>PROVIDENCE</CityNm>
          <StateAbbreviationCd>RI</StateAbbreviationCd>
          <ZIPCd>02903</ZIPCd>
        </USAddress>
        <RecipientEIN>222538470</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>5177</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CHILDREN'S HOSPITAL OF PITTSBURGH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>4401 PENN AVE</AddressLine1Txt>
          <CityNm>PITTSBURGH</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>15224</ZIPCd>
        </USAddress>
        <RecipientEIN>251865744</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>6933</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3333 BURNET AVE</AddressLine1Txt>
          <CityNm>CINCINNATI</CityNm>
          <StateAbbreviationCd>OH</StateAbbreviationCd>
          <ZIPCd>45229</ZIPCd>
        </USAddress>
        <RecipientEIN>310833936</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>10501</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>OKLAHOMA CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1200 CHILDRENS AVE</AddressLine1Txt>
          <CityNm>OKLAHOMA CITY</CityNm>
          <StateAbbreviationCd>OK</StateAbbreviationCd>
          <ZIPCd>73104</ZIPCd>
        </USAddress>
        <RecipientEIN>731200262</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>13421</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>SOCIETY OF NEUROONCOLOGY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 273296</AddressLine1Txt>
          <CityNm>HOUSTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>772773296</ZIPCd>
        </USAddress>
        <RecipientEIN>760499664</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>8000</CashGrantAmt>
        <PurposeOfGrantTxt>SYMPOSIUM EXPENSES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 301439 UNIT 705</AddressLine1Txt>
          <CityNm>HOUSTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77030</ZIPCd>
        </USAddress>
        <RecipientEIN>746001118</RecipientEIN>
        <IRCSectionDesc>GOVT</IRCSectionDesc>
        <CashGrantAmt>7862</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>OSF HEALTHCARE CHILDREN'S HOSPITAL OF ILLINOIS</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>530 NE GLEN OAK AVE</AddressLine1Txt>
          <CityNm>PEORIA</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>61637</ZIPCd>
        </USAddress>
        <RecipientEIN>370813229</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>6673</CashGrantAmt>
        <PurposeOfGrantTxt>VS. CANCER GRANT</PurposeOfGrantTxt>
      </RecipientTable>
      <Total501c3OrgCnt>29</Total501c3OrgCnt>
      <GrantsOtherAsstToIndivInUSGrp>
        <GrantTypeTxt>DIRECT ASSISTANCE TO INDIVIDUALS</GrantTypeTxt>
        <CashGrantAmt>459794</CashGrantAmt>
      </GrantsOtherAsstToIndivInUSGrp>
      <GrantsOtherAsstToIndivInUSGrp>
        <GrantTypeTxt>SCHOLARSHIPS</GrantTypeTxt>
      </GrantsOtherAsstToIndivInUSGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>ALL ANNUAL RESEARCH GRANTS ARE REVIEWED BY OUR RESEARCH ADVISORY NETWORK AND EVALUATED ON SEVERAL CRITERIA, INCLUDING SCIENTIFIC MERIT OF THE GRANT APPLICATION; SCIENTIFIC BACKGROUND OF THE RESEARCHERS; THE PEER REVIEWED RESEARCH PUBLICATIONS OF THE PRINCIPLE INVESTIGATORS APPLYING; THE SUPPORTING COLLABORATIVE RESEARCH ENVIRONMENT IN THE RESEARCH INSTITUTION; AND THE VIABILITY OF RESEARCH PROPOSED, AND FACILITIES AVAILABLE. EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT PERIODIC UPDATES, AND A FINAL REPORT BEFORE THE FINAL GRANT PAYMENT IS MADE. EACH RESEARCH APPLICATION HAS TO HAVE A HYPOTHESIS DRIVEN RESEARCH PROPOSAL. EACH APPLICATION MUST HAVE A LIST OF SPECIFIC AIMS THAT ARE TO BE ACHIEVED OVER THE TIMELINE OF THE RESEARCH PROJECT. A TIME LINE IS REQUESTED FOR THE ACHIEVEMENT OF THE SPECIFIC AIMS. THE PROGRESS REPORTS REQUIRE THAT THE ACHIEVEMENT OF SPECIFIC AIMS BE DETAILED WITH A SCIENTIFIC DESCRIPTION OF THE MANNER IN WHICH THEY WERE ACHIEVED. IF AN EVENT HAS OCCURRED THAT ALTERS THE ACHIEVEMENT OF THE SPECIFIC AIMS WITHIN THE TIME LINE OF THE RESEARCH PLAN THE RESEARCHERS MUST GIVE A REASON THAT IT HAS NOT BEEN ACHIEVED AND A NO COST EXTENSION MAY BE REQUESTED AND A NEW TIMELINE IS ESTABLISHED BEFORE THE FINAL PROGRESS REPORT IS ISSUED. EACH GRANT ALLOWS FOR THE OPPORTUNITY OF A SITE VISIT BY THE PBTF AND THESE SITE VISITS ARE MADE BY THE DIRECTOR OF RESEARCH AS WELL AS THE SENIOR SCIENTIFIC RESEARCH ADVISOR, THE PBTF PRESIDENT AS WELL AS THE EXECUTIVE DIRECTOR. RESEARCHERS PRESENT THEIR RESEARCH RESULTS IN PERSON AND THE PBTF ASKS QUESTIONS ABOUT THE RESULTS. ALL GRANT APPLICATIONS AND RESEARCH PROJECTS HAVE THE SAME REQUIREMENTS ON GRANT APPROVAL AND REPORTING REGARDLESS OF THE LOCATION OF THE RESEARCHER AND HIS/HER INSTITUTION. THESE REPORTS ARE REVIEWED BY OUR DIRECTOR OF RESEARCH FUNDING AND OUR CONTRACTED SENIOR SCIENTIFIC RESEARCH ADVISOR. FINAL APPROVAL ON ALL GRANTS IS CONDITIONED ON BOARD OF DIRECTOR APPROVAL.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="RetDoc1042400001">
      <Form990OfOtherOrganizationsInd>X</Form990OfOtherOrganizationsInd>
      <CompensationSurveyInd>X</CompensationSurveyInd>
      <BoardOrCommitteeApprovalInd>X</BoardOrCommitteeApprovalInd>
      <SeverancePaymentInd>0</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>0</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>0</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>0</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>0</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>0</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>0</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>0</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>0</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>COURTNEY DAVIES</PersonNm>
        <TitleTxt>PRESIDENT/CEO</TitleTxt>
        <BaseCompensationFilingOrgAmt>275380</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>0</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>275380</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
    </IRS990ScheduleJ>
    <IRS990ScheduleM documentId="RetDoc1042900001">
      <CarsAndOtherVehiclesGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <ContributionCnt>5</ContributionCnt>
        <NoncashContributionsRptF990Amt>58496</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>FAIR MARKET VALUE</MethodOfDeterminingRevenuesTxt>
      </CarsAndOtherVehiclesGrp>
      <AnyPropertyThatMustBeHeldInd>0</AnyPropertyThatMustBeHeldInd>
      <ReviewProcessUnusualNCGiftsInd>1</ReviewProcessUnusualNCGiftsInd>
      <ThirdPartiesUsedInd>0</ThirdPartiesUsedInd>
    </IRS990ScheduleM>
    <IRS990ScheduleO documentId="RetDoc1044400001">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III LINE 4A</FormAndLineReferenceDesc>
        <ExplanationTxt>WHILE COVID-19 CONTINUED TO INCREASE THE HEAVY TOLL A CHILD'S BRAIN TUMOR TAKES ON FAMILIES AND THREATENED PROGRESS TOWARDS A CURE, THE PEDIATRIC BRAIN TUMOR FOUNDATION LED THE CHILDHOOD BRAIN CANCER COMMUNITY IN CONTINUING TO PUSH FORWARD RESEARCH PROJECTS THAT ARE ACCELERATING THE DISCOVERY OF TARGETED THERAPIES, FAMILY SUPPORT PROGRAMS THAT ARE LESSENING THE EMOTIONAL, ECONOMIC, AND PHYSICAL IMPACT OF A CHILD'S BRAIN TUMOR DIAGNOSIS, AND ADVOCACY INITIATIVES THAT ARE RAISING AWARENESS ABOUT THE NEED TO IMPROVE OUTCOMES FOR PATIENT AND INCREASE FUNDING OF PEDIATRIC BRAIN TUMOR SCIENTIFIC RESEARCH. SUMMARY OF 2021 RESEARCH INVESTMENTS: PBTF'S MOMENTUM IN FUNDING CUTTING-EDGE PEDIATRIC BRAIN TUMOR RESEARCH IN 2021, DESPITE THE LINGERING IMPACT AND SLOWDOWNS AS A RESULT OF THE PANDEMIC, CONTINUED TO PICK UP SPEED. ALL EXISTING GRANTS CONTINUED IN THEIR PROGRESS AND NEW RESEARCH INITIATIVES WERE LAUNCHED. PBTF EMBRACED THE SCIENTIFIC COMMUNITY AND REINFORCED OUR COMMITMENT TO CONTINUING TO SUPPORT THEIR LIFE-CHANGING PROJECTS. THE PEDIATRIC BRAIN TUMOR FOUNDATION'S RESEARCH MISSION IS GUIDED BY OUR COMMITMENT TO MAXIMIZE THE NUMBER OF LIFE-CHANGING THERAPIES MOVING FROM DEVELOPMENT THROUGH COMMERCIALIZATION TO FIND TARGETED TREATMENTS FOR ALL KIDS BATTLING BRAIN TUMORS. THE FOLLOWING ARE PROJECTS THAT RECEIVED FUNDING FROM PBTF IN 2021 BASED ON THE SPECIFIC STRATEGIC INVESTMENT CATEGORY UNDER WHICH IT FALLS. BASIC SCIENCE AND CORE PROJECT RESOURCES: INVESTING IN NOVEL BASIC SCIENCE CONCEPTS AND CORE RESOURCES IN THE PEDIATRIC BRAIN TUMOR RESEARCH FIELD IS ESSENTIAL TO PBTF'S RESEARCH INVESTMENT STRATEGY. THERE ARE FEW FUNDING SOURCES AVAILABLE TO SCIENTISTS WHO ARE FOCUSED ON 'OUT OF THE BOX' IDEAS FOR CRACKING THE CODE ON ERADICATING PEDIATRIC BRAIN TUMORS; PBTF'S COMMITMENT TO BASIC SCIENCE AND CORE PROJECT RESOURCES PROVIDES THE FINANCIAL SUPPORT AND OPPORTUNITIES THAT RESEARCHERS NEED TO TEST PROMISING NEW HYPOTHESES THAT WILL LEAD TO THE NEXT TARGETED THERAPY. PBTF'S PARTNERSHIP WITH THE BRAIN TUMOR FUNDERS COLLABORATIVE ENTERED ITS THIRD YEAR IN SUPPORT OF THE IMMUNOTHERAPY RESEARCH INITIATIVE FOR THE PROJECT AT THE UNIVERSITY OF PITTSBURGH ENTITLED "INTERROGATING ANTI-TUMOR T-CELLS TO DEVELOP ADOPTIVE CELL TRANSFER (ACT) IMMUNOTHERAPY FOR PEDIATRIC HIGH-GRADE GLIOMAS" UNDER THE DIRECTION OF PRINCIPAL INVESTIGATOR DR. GARY KORNBASCH. $112,500 WAS PAID TO THE BTFC IN 2021 TO COVER THIS GRANT WITH A TOTAL INVESTMENT COMMITMENT OF $450,000 OVER THREE YEARS. HARNESSING THE PEDIATRIC HIGH-GRADE GLIOMA PATIENT'S IMMUNE SYSTEM TO ATTACK THE TUMOR IS A NOVEL IDEA IN THE TREATMENT OF ONE OF THE DEADLIEST TYPES OF BRAIN TUMORS. DRS. CASTRO AND LOWENSTEIN FROM THE UNIVERSITY OF MICHIGAN'S CHAD CARR PEDIATRIC BRAIN TUMOR CENTER ARE GRANT AWARDEES FOR A MULTI-YEAR PROJECT ENTITLED "NOVEL IMMUNE MEDIATED-GENE THERAPY FOR PEDIATRIC HIGH-GRADE GLIOMA" WITH AN AWARD TOTALING $669,533. AT THE INVESTIGATORS' REQUEST, THIS AWARD HAS BEEN EXTENDED THROUGH 2022 WITH AN UPCOMING FINAL PAYMENT OF $219,844. IN 2021, PBTF EMBARKED ON A NEW GRANT AWARD WITH THE UNIVERSITY OF MICHIGAN FOR A PROJECT ENTITLED "RAPID MOLECULAR TESTING OF HIGH GRADE GLIOMAS." IN THIS STUDY, THE INVESTIGATORS LEVERAGE LAMP AMPLIFICATION TECHNOLOGY AND HANDHELD ELECTRONIC SEQUENCING TO ANALYZE MOLECULAR ALTERATIONS, DELETIONS AND MUTATIONS IN BLOOD AND FLUID SAMPLES FROM PATIENTS BATTLING THE MOST AGGRESSIVE FORMS OF PEDIATRIC BRAIN TUMORS. THE AIM OF THE PROJECT IS TO DEVELOP A TECHNIQUE FOR A MORE RAPID DIAGNOSIS OF TUMORS IN ORDER FOR CLINICIANS TO MORE ACCURATELY PRESCRIBE TARGETED TREATMENTS FOR THE SPECIFIC ANOMALIES THAT ARE IDENTIFIED BEFORE THE TUMOR MUTATES INTO A DIFFERENT FORM. THIS IS A ONE-YEAR AWARD IN THE AMOUNT OF $70,000. PEDIATRIC DRUG DOSING IS AN UNDERSTUDIED AREA AS MOST CLINICAL TRIALS DETERMINE DRUG DOSING RECOMMENDATIONS FOR PHASE I TRIALS IN KIDS BASED ON ADULT STANDARDS. IN ORDER TO DEVELOP STANDARDS FOR MORE EFFECTIVE DRUG DOSING IN KIDS, PBTF FUNDED A RESEARCH PROJECT ENTITLED "FUNCTIONAL ENGAGEMENT AND EFFECT OF RAF-TARGETED THERAPIES IN GLIOMAS" IN PARTNERSHIP WITH THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. THE PRINCIPAL INVESTIGATOR FOR THE AWARD IS DR. KARISA SCHRECK AT JOHNS HOPKINS MEDICAL CENTER. THE TOTAL AWARD IS $200,000 OVER TWO YEARS. THE FINAL PAYMENT OF $90,000 WAS DISTRIBUTED IN 2021. IN 2021, A FINAL PAYMENT IN THE AMOUNT OF $66,000 WAS DELIVERED TO THE DANA FARBER CANCER INSTITUTE IN SUPPORT OF A TWO-YEAR CORE RESOURCE COMMITMENT TO SUPPORT THE HIRING OF A CLINICAL RESEARCH ASSISTANT (TOTAL AWARD $132,000). THIS INDIVIDUAL IS RESPONSIBLE FOR TUMOR TISSUE COLLECTION BY OBTAINING PARENTS' CONSENT O PRIOR TO SURGERY AND SHEPHERDING TISSUE HARVESTING DURING SURGERIES AND BIOPSIES. WITH AN INCREASE IN VIABLE TISSUE SAMPLES, SCIENTIFIC RESEARCH IS FUELED WITH MATERIAL TO TEST NEW HYPOTHESES AND POTENTIAL TREATMENT OPTIONS. THE MULTI-INSTITUTIONAL GRANT ENTITLED "OPTIMIZING OUTCOMES FOR PLGG PATIENTS" AWARDED FUNDS TO TWO OF THE THREE INSTITUTIONS ENGAGED IN THIS PROJECT. CHILDREN'S NATIONAL MEDICAL CENTER RECEIVED $28,593 AND CHILDREN'S HOSPITAL OF ATLANTA RECEIVED $8,210 AS THE PROJECT ENTERED THE SECOND YEAR OF PRODUCTIVITY. THE PURPOSE OF THIS PROJECT IS TO PERFORM A META ANALYSIS ON A COHORT OF PLGA SURVIVORS, ANALYZING THE OUTCOMES BASED ON QUALITY OF LIFE, TREATMENTS AND SPECIFIC MOLECULAR MUTATION. THE TOTAL GRANT AWARD FOR THIS PROJECT IS $364,141 OVER THREE YEARS. WASHINGTON UNIVERSITY OF ST. LOUIS'S PROJECT ENTITLED "HUMAN IPSC PLGA MODELS FOR THERAPEUTIC DRUG DISCOVERY AND EVALUATION" RECEIVED A SECOND YEAR OF FUNDING IN THE AMOUNT OF $100,000 IN 2021. THIS PROJECT (TOTAL OF 3 YEARS) IS WORKING TO CREATE A MOUSE MODEL FOR PLGA BRAIN TUMORS. WITHOUT MOUSE MODELS, SCIENTISTS ARE HAMPERED IN TESTING NEW THERAPIES AGAINST THE SPECIFIC TUMOR MUTATION WHICH IN TURN SLOWS THE PIPELINE OF THERAPY DEVELOPMENT. EARLY CAREER DEVELOPMENT AWARDEES FROM DUKE UNIVERSITY AND CHILDREN'S HOSPITAL OF CINCINNATI BOTH RECEIVED GRANT FUNDING IN 2021 TO SUPPORT PROJECTS ENTITLED "IDENTIFYING BRAINSTEM GLIOMA SUBTYPES THAT CAN BE RADIOSENSITIZED BY ATM INHIBITION AND "MAINTENANCE OF DIPG BLOOD-BRAIN BARRIER INTEGRITY BY ANGIOPOLETIN1" RESPECTIVELY. BOTH PROJECTS RECEIVED $150,000 FOR A TOTAL OF $300,000, WHICH IS PART OF A THREE YEAR GRANT AWARD. THESE PROJECTS WERE IN THEIR SECOND YEAR OF FUNDING IN 2021. GLOBAL TRAINING/EDUCATION: INTERNATIONAL COLLABORATION IN THE SCIENTIFIC COMMUNITY IS THE SINGLE MOST IMPORTANT INGREDIENT IN ACCELERATING RESEARCH PRODUCTIVITY. PBTF'S SUPPORT FOR ACADEMIC-DRIVEN INTERNATIONAL RESEARCH MEETINGS SPURS INNOVATION AND FACILITATES THE SHARING OF TIMELY RESEARCH DISCOVERIES ACROSS DISCIPLINES, SUB-SPECIALTIES, COUNTRIES, AND INSTITUTIONS. IN 2021, PBTF SPONSORED THE SOCIETY OF NEUROONCOLOGY'S PEDIATRIC BRAIN TUMOR BASIC AND TRANSLATIONAL SCIENCE CONFERENCE WHICH WAS CONVENED VIRTUALLY IN 2021. SCIENTIFIC MEETINGS SUCH AS THESE ARE A CRITICAL CORNERSTONE FOR THE RESEARCH COMMUNITY TO CONNECT AND SHARE REAL TIME DATA AND RESULTS, BUILD RELATIONSHIPS AND BREAKDOWN SILOS IN ORDER TO ACCELERATE THE PACE OF CUTTING-EDGE RESEARCH. THE SPONSORSHIP WAS $8,000 FOR THIS PREEMINENT MEETING. CLINICAL TRIALS: WHILE COVID DELAYED THE PACE OF MANY PROJECTS IN 2020 -- ESPECIALLY CLINICAL TRIALS, 2021 SAW A RESURGENCE OF TRIALS RE-OPENING FOR ENROLLMENT. THESE TRIALS CHALLENGE 'GOLD STANDARD' TREATMENTS AND EXPLORE NEW POSSIBILITIES FOR CHILDREN WHO HAVE RUN OUT OF OTHER EFFECTIVE TREATMENT OPTIONS. IN 2021, PBTF AWARDED CLINICAL TRIAL GRANTS TO: THE PEDIATRIC PACIFIC NEURO ONCOLOGY CONSORTIUM (PNOC) FOR A TRIAL ENTITLED "PNOC021-COMBINATORIAL CLINICAL TRIAL" WITH THE FUNDS BENEFITING THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. THIS IS A MULTI-YEAR AWARD TOTALING $300,000 WITH $100,000 DISBURSED IN 2021. THE DANA FARBER CANCER INSTITUTE (DFCI) FOR A TRIAL ENTITLED, "PHASE I/II TRIAL OF MEK162 IN LOW GRADE GLIOMA". THIS IS A MULTI-YEAR AWARD TOTALING $249,500 WITH $124,750 DISBURSED IN 2021. PROJECT OPEN DIPG IS A CONTINUATION OF A GRANT AWARDED IN 2019 FOR A CLINICAL TRIAL ENTITLED "PHASE 1 TRIAL OF MARIZOMIB ALONE AND IN COMBINATION WITH PANOBINOSTAT FOR CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA". THIS STUDY WAS PAUSED FOR ENROLLMENT IN 2020 AND EARLY 2021 DUE TO THE PANDEMIC; HOWEVER, IT HAS REOPENED AND IS MOVING FORWARD. THE GRANT AWARD WAS FOR $16,667 WHICH WAS FUNDED IN 2019, WITH THE GRANTEE REQUESTING A NO-COST EXTENSION THROUGH DECEMBER 2022.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III LINE 4A CONTINUED</FormAndLineReferenceDesc>
        <ExplanationTxt>FAMILY SUPPORT PROGRAM SERVICE ACCOMPLISHMENTS FROM COVID-19'S IMPACT ON PATIENTS' HEALTH AND FAMILIES' FINANCIAL STABILITY TO THE UNINTENDED CONSEQUENCES OF STRINGENT HOSPITAL SAFETY PROTOCOLS ON PATIENT CARE, THE PANDEMIC CONTINUED TO POSE SIGNIFICANT RISKS TO CHILDREN WITH BRAIN TUMORS AND THEIR FAMILIES IN 2021. BY CONTINUING TO IMPROVE THE ORGANIZATION'S APPROACH TO PATIENT FAMILY FOLLOW-UP, GROWING OUR COLLABORATIONS WITH HOSPITAL CARE PARTNERS, AND EXPANDING VIRTUAL OFFERINGS TO INCLUDE NEW SUPPORT GROUPS AND DIGITAL RESOURCES, PBTF INCREASED ITS ENGAGEMENT WITH FAMILIES BY 14.5% YEAR-OVER-YEAR AND INCREASED ITS REACH TO NEW FAMILIES BY 36.3% YEAR-OVER-YEAR. PBTF'S MONTHLY WEBINAR SERIES CONTINUED TO GROW IN 2021, WITH 10 WEBINARS COVERING THE FULL CONTINUUM OF CARE. INFORMED BY PATIENT FAMILY FEEDBACK, TOPICS FOCUSED ON NAVIGATING THE EMOTIONAL, INFORMATIONAL, AND LOGISTICAL CHALLENGES OF THE PEDIATRIC BRAIN TUMOR JOURNEY, INCLUDING EXPLORING TARGETED THERAPIES, UNDERSTANDING PEDIATRIC BRAIN TUMOR TYPES AND TREATMENTS, ENGAGING IN ADVOCACY, AND NAVIGATING SOCIAL SKILLS CHALLENGES. PATIENT FAMILIES RESPONDED POSITIVELY TO THIS YEAR'S TOPICS, WITH ATTENDANCE RATES INCREASING FROM 49% TO 55% YEAR-OVER-YEAR. AS PART OF PBTF'S COMMITMENT TO HELPING PATIENT FAMILIES NAVIGATE THE CHALLENGES OF COVID-19, PBTF'S JUNE WEBINAR WELCOMED THREE RENOWNED EXPERTS TO DISCUSS THE CURRENT STATE OF COVID-19 VACCINE STUDIES IN CHILDREN AND CONSIDERATIONS FOR VACCINATING CHILDREN IN TREATMENT AND POST-TREATMENT FOR A BRAIN TUMOR. PBTF'S SUPPORT OF FAMILIES THROUGH THE BUTTERFLY FUND DELIVERED $456,962.40 IN FINANCIAL RELIEF (A 3% INCREASE YEAR-OVER-YEAR), WITH $1258 PROVIDED TO EACH FAMILY ON AVERAGE. OUR BUTTERFLY FUND PARTNER HOSPITAL NETWORK ALSO EXPANDED TO PROVIDE AID TO PEDIATRIC BRAIN TUMOR PATIENTS IN TREATMENT AT C.S. MOTT CHILDREN'S HOSPITAL, INCREASING THE TOTAL NUMBER OF HOSPITAL PARTNERS TO 19 INSTITUTIONS NATIONWIDE. 52.3% OF BUTTERFLY FUND SUPPORT IN 2021 ASSISTED FAMILIES WITH HOUSING NEEDS, WITH OTHER KEY AREAS OF FINANCIAL ASSISTANCE INCLUDING SUPPORT FOR FUNERALS AND TRAVEL FOR TREATMENT. THE NATIONAL PEER TO PEER MENTORING PROGRAM CONTINUED TO GROW, WITH A 125% YEAR-OVER-YEAR INCREASE OF PATIENT FAMILIES MATCHED WITH TRAINED MENTORS WHO HAVE EXPERIENCED THE CHALLENGES OF THE CHILDHOOD BRAIN TUMOR JOURNEY. PBTF EXPANDED ITS SUPPORT OF THE HISPANIC AND LATINX PATIENT FAMILY COMMUNITY WITH THE INTRODUCTION OF THE STARFOLIO RESOURCE GUIDEBOOK IN SPANISH AND BROADENING OUR MONTHLY, CALIFORNIA-BASED SPANISH-LANGUAGE SUPPORT GROUPS TO REACH A NATIONWIDE PATIENT FAMILY AUDIENCE. ALTHOUGH PANDEMIC-RELATED CANCELLATIONS OF IN-PERSON SCHOOL AND SPORTS ACTIVITIES CONTINUED TO ADVERSELY IMPACT VS. CANCER FUNDRAISING EFFORTS THAT DIRECTLY FUND HOSPITAL GRANTS IN TEAMS' LOCAL COMMUNITIES, PBTF WAS ABLE TO CONTINUE ITS SUPPORT OF CRITICAL PEDIATRIC PATIENT SUPPORT PROGRAMS AT 49 HOSPITALS. PBTF'S VS. CANCER GRANTS REACHED 1203 PEDIATRIC BRAIN TUMOR FAMILIES IN 2021 AND SAFEGUARDED INITIATIVES SUCH AS: - UMASS MEMORIAL HEALTH'S MUSIC THERAPY THERAPY PROGRAM: UMASS MEMORIAL HEALTH HAS BEEN ABLE TO INCREASE THEIR MUSIC THERAPIST'S SCHEDULE IN THE LAST FOUR YEARS, SPECIFICALLY NOW PROVIDING SUPPORT TO THE HEMATOLOGY/ONCOLOGY CLINIC. EACH WEEK THE MUSIC THERAPIST WORKS 20 HOURS ON THE INPATIENT FLOOR AND 4 HOURS IN THE PEDIATRIC OUTPATIENT HEMATOLOGY/ONCOLOGY CLINIC. THE THERAPIST SEES PATIENTS INDIVIDUALLY AT THEIR BEDSIDE OR INFUSION CHAIR OR IN THE HOSPITAL'S PLAYROOM, TEACHING EVIDENCE-BASED METHODS TO RELAX AND MANAGE ANXIETY WITH MEANINGFUL, PATIENT-SELECTED ACTIVITIES. - MD ANDERSON'S AYA SCHOLARSHIPS: ADOLESCENTS AND YOUNG ADULTS HAVE EDUCATIONAL AND CAREER GOALS THAT ARE OFTEN DERAILED BY THEIR CANCER DIAGNOSIS/TREATMENT. EVEN AFTER TREATMENT IS OVER AND THEY WORK ON RECOVERING FROM THE PHYSICAL DAMAGE THAT HAS BEEN DONE, MANY PATIENTS/FAMILIES HAVE EXHAUSTED THEIR FINANCIAL SAVINGS TO PAY FOR CANCER TREATMENT. THE MD ANDERSON AYA SCHOLARSHIP HELPS PATIENTS PURSUE THEIR LIFE AND CAREER GOALS THROUGH VOCATIONAL SCHOOLS, COMMUNITY COLLEGE, FOUR-YEAR UNIVERSITIES, AND POST-GRADUATE PROGRAMS. - PHOENIX CHILDREN'S HARDSHIP FUND: VS. CANCER FUNDING PROVIDED BY PBTF TO PHOENIX CHILDREN'S HOSPITAL ADDRESSES THE FINANCIAL STRESS A FAMILY FACES WHEN RECEIVING TREATMENT. PHOENIX CHILDREN'S HISTORICALLY SERVES LOW-TO-MODERATE INCOME FAMILIES WITH 50% OR MORE OF THE FAMILIES LIVING AT OR BELOW POVERTY LEVEL. THEIR HARDSHIP FUND COVERS INCIDENTAL COSTS ASSOCIATED WITH HOSPITAL STAYS INCLUDING MEAL ASSISTANCE, GAS, LODGING AND TRANSPORTATION. FUNDING FROM PBTF'S 2021 VS. CANCER GRANT WILL SERVE APPROXIMATELY 84 FAMILIES. - DUKE'S PEDIATRIC NEUROPSYCHOLOGY PATIENT EVALUATION EFFORTS: THE LEARNING NEEDS OF PEDIATRIC BRAIN TUMOR PATIENTS ARE UNIQUE AND COMPLEX. DUKE'S PEDIATRIC NEUROPSYCHOLOGISTS PARTNER WITH MEMBERS OF THE SOCIAL WORK TEAM TO OUTLINE NECESSARY SUPPORT AT SCHOOL AND TO GUIDE ADVOCACY FOR ACCESSING THOSE SUPPORTS. THE RECOMMENDATIONS ARE BASED ON COGNITIVE SCREENING TOOLS AND OTHER COMPREHENSIVE EVALUATIONS FUNDED BY PBTF'S VS. CANCER GRANT. IT IS ANTICIPATED THAT APPROXIMATELY 30 PEDIATRIC BRAIN TUMOR PATIENTS WILL BENEFIT IN THE PROGRAM FROM THIS GRANT. PBTF LEADERSHIP ALSO SHARED FAMILY SUPPORT INSIGHTS WITH THE BROADER HEALTHCARE AND MEDICAL COMMUNITIES BY PRESENTING AND EXHIBITING AT THE ANNUAL MEETINGS FOR THE SOCIETY FOR NEUROONCOLOGY, ASSOCIATION OF PEDIATRIC ONCOLOGY SOCIAL WORKERS AND ASSOCIATION OF PEDIATRIC HEMATOLOGY ONCOLOGY NURSES. 2021 EXPANSION OF PBTF'S ADVOCACY LEADERSHIP PBTF'S MISSION OF CARE. CURE. THRIVE. IS ACHIEVED THROUGH FOCUSED PROGRAMS TO SUPPORT FAMILIES AS THEY NAVIGATE THE PEDIATRIC BRAIN TUMOR JOURNEY, AS WELL AS SUPPORT SCIENTISTS IN DISCOVERING NOVEL, MORE EFFECTIVE TREATMENTS FOR ALL TYPES OF BRAIN TUMORS IN KIDS. THESE EFFORTS ARE STRENGTHENED BY THE PBTF'S ADVOCACY INITIATIVES WHICH HELP SHINE THE SPOTLIGHT ON THIS PERNICIOUS DISEASE, THE #1 CAUSE OF CANCER DEATH IN KIDS. WHILE PBTF'S ADVOCACY SERVICES AND PROGRAMS ARE NON-GRANT BEARING, THEY DO HAVE A MAJOR IMPACT ON THE LEGISLATION THAT IS PASSED AND BRING ATTENTION TO THE DISEASE IN A BROADER CONTEXT THAN JUST THE CHILDHOOD CANCER COMMUNITY. IN ADDITION TO OUR DIRECT PATIENT ADVOCACY SUPPORT OF FAMILIES, PBTF CONTINUED TO SERVE AS THE LEADING CHAMPION FOR THE PEDIATRIC BRAIN TUMOR COMMUNITY THROUGH THE FOLLOWING INITIATIVES. IN 2021, THE PBTF WAS AN ACTIVE PARTICIPANT IN TWO LEGISLATIVE ADVOCACY DAYS ON CAPITOL HILL: - ACTION DAYS (APRIL 27, 2021): IN PARTNERSHIP WITH THE ALLIANCE FOR CHILDHOOD CANCER, ACTION DAYS RESULTED IN OVER 300 PEDIATRIC CANCER ADVOCATES FROM 39 STATES WHO MET WITH OVER 200 CONGRESSIONAL LEADERS TO AMPLIFY THE VOICES OF THE CHILDHOOD CANCER COMMUNITY. - HEAD TO THE HILL (MAY 4, 2021): IN PARTNERSHIP WITH THE NATIONAL BRAIN TUMOR SOCIETY, HEAD TO THE HILL RESULTED IN 410 BRAIN TUMOR ADVOCATES FROM 46 STATES TAKING PART IN 286 CONGRESSIONAL MEETINGS TO DO THE SAME. BOTH EFFORTS INCLUDED CONGRESSIONAL 'ASKS' WHICH WOULD RESULT IN CONTINUED FUNDING OF SPECIFIC PEDIATRIC CANCER AND PEDIATRIC BRAIN TUMOR RESEARCH INVESTMENTS THROUGH EXISTING LEGISLATION. THESE PEDIATRIC CANCER AND BRAIN CANCER ADVOCACY EFFORTS ARE DRIVING OUTCOMES FOR THE PATIENTS WE SERVE BY HELPING TO RAISE AWARENESS AND ENSURE THAT PEDIATRIC BRAIN TUMOR SCIENTIFIC RESEARCH IS PROPERLY FUNDED. PBTF IS PROUD OF THE ADVOCATES THAT ARE HELPING TO DRIVE BETTER OUTCOMES BY ENSURING THAT THE FUNDING FOR PEDIATRIC BRAIN TUMOR SCIENTIFIC RESEARCH IS AVAILABLE. FURTHERMORE, PBTF ESTABLISHED A LEADERSHIP POSITION IN THE COALITION AGAINST CHILDHOOD CANCER (CAC2) WITH THE INSTALLATION OF PBTF'S NATIONAL DIRECTOR OF RESEARCH AND ADVOCACY AS CAC2'S CURRENT BOARD CHAIR. THE MISSION OF THIS VOLUNTEER-LED, MEMBERSHIP-BASED ORGANIZATION IS TO FOSTER AND SUSTAIN GREATER LEVELS OF COORDINATED ACTION, INFORMATION EXCHANGE, EDUCATION AND LEARNING AND BROAD-BASED COLLABORATION BETWEEN KEY STAKEHOLDERS IN THE CHILDHOOD CANCER ARENA. THE OUTCOME OF WHICH IS TO DRAW GREATER ATTENTION AND RESOURCES TO THE DEADLIEST CHILDHOOD DISEASE IN ORDER TO CHANGE THE OUTCOME AND INCREASE RESOURCES FOR ALL CHILDREN UNDERGOING A CANCER DIAGNOSIS. A NUMBER OF CAC2'S PIVOTAL PROJECTS WERE DESIGNED AND IMPLEMENTED UNDER THE STEWARDSHIP OF THE NEW BOARD CHAIR INCLUDING THE #CANCELCHILDHOODCANCER CAMPAIGN; AN ENDORSEMENT LETTER SIGN-ON INITIATIVE; RESEARCHING, WRITING AND PRESENTING AT SIOP A NEW ETHICS DISCUSSION ENTITLED "DEVELOPING A WORKING PAPER TO CULTIVATE ETHICALLY SUSTAINABLE RELATIONSHIPS AMONG STAKEHOLDERS WHEN NONPROFITS FUND PEDIATRIC CANCER TRIALS; AND A NUMBER OF OTHER PROJECTS. ALL OF THESE EFFORTS SERVE TO DRAW FURTHER ATTENTION TO THIS DISEASE ON A LOCAL, NATIONAL AND GLOBAL SCALE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III LINE 4A CONTINUED</FormAndLineReferenceDesc>
        <ExplanationTxt>IN 2021, PBTF ALSO SUPPORTED CUREFEST, THE NATION'S LARGEST FAMILY-LED, FAMILY-ATTENDED ADVOCACY EVENT IN WASHINGTON, DC ON SEPTEMBER 24TH WITH A $1700 GRANT. THIS EVENT DREW ATTENDEES FROM 50 STATES AND 68 COUNTRIES AND WAS LIVE STREAMED TO OVER 36,000 VIEWERS ACROSS THE GLOBE. THE OBJECTIVE OF THE EVENT IS TO DRAW ATTENTION TO THE PLIGHT OF PEDIATRIC CANCER PATIENTS AND THEIR FAMILIES AND ENGAGE IN PRODUCTIVE CONVERSATIONS AND RELATIONSHIP BUILDING EVENTS BETWEEN PATIENTS, FAMILIES, SURVIVORS, NON-PROFIT ORGANIZATIONS, LEGISLATORS, MEDIA, AND THE GENERAL PUBLIC. WHILE THIS EVENT TARGETS THE WIDER CHILDHOOD CANCER AUDIENCE, THE SUPPORT FROM PBTF WAS LEVERAGED IN PARTNERSHIP WITH THE DIPG COMMUNITY TO HOST THE INAUGURAL SUNRISE RESEARCH/CLINICIAN SESSION AND BREAKFAST. WITH OVER 210 ATTENDEES ATTENDING THIS NEWEST EVENT, THERE WAS GREAT ENERGY AROUND CHANGING OUTCOMES FOR CHILDREN BATTLING THE DEADLIEST OF BRAIN TUMORS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION A, LINE 1</FormAndLineReferenceDesc>
        <ExplanationTxt>THE BOARD OF DIRECTORS MAY, BY RESOLUTION, DESIGNATE TWO (2) OR MORE DIRECTORS TO CONSTITUTE AN EXECUTIVE COMMITTEE, WHICH COMMITTEE, TO THE EXTENT PROVIDED IN SUCH RESOLUTION, SHALL HAVE AND MAY EXERCISE ALL OF THE AUTHORITY OF THE BOARD OF DIRECTORS IN THE MANAGEMENT OF THE CORPORATION EXCEPT AS OTHERWISE REQUIRED BY LAW. ALL MEMBERS OF THE EXECUTIVE COMMITTEE SHALL BE DIRECTORS OF THE CORPORATION. VACANCIES IN THE MEMBERSHIP OF THE COMMITTEE SHALL BE FILLED BY THE BOARD OF DIRECTORS AT ANY ANNUAL OR SPECIAL MEETING OF THE BOARD OF DIRECTORS. THE EXECUTIVE COMMITTEE SHALL KEEP REGULAR MINUTES OF ITS PROCEEDINGS AND REPORT THE SAME TO THE BOARD.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 11B</FormAndLineReferenceDesc>
        <ExplanationTxt>THE RETURN WAS PREPARED BY AN INDEPENDENT ACCOUNTANT WITH ASSISTANCE AND OVERSIGHT BY MANAGEMENT. THE CFO AND PRESIDENT REVIEWED THE RETURN WITH THE PREPARERS AT MULTIPLE STAGES OF COMPLETION. UPON RECEIVING A FINAL DRAFT, THE RETURN WAS PRESENTED AT A SCHEDULED BOARD MEETING. THE RETURN WAS PRESENTED TO THE FULL BOARD BY A MEMBER OF THE ACCOUNTING FIRM AND THE MANAGEMENT OF THE ORGANIZATION, AND A PERIOD OF TIME FOR QUESTIONS AND COMMENTS WAS ALLOWED.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 12C</FormAndLineReferenceDesc>
        <ExplanationTxt>ALL FINANCIAL TRANSACTIONS (BOTH REVENUE AND EXPENSE) ARE CONDUCTED WITH THE KNOWLEDGE AND/OR APPROVAL OF EITHER THE PRESIDENT/CEO OR THE CFO. THESE TRANSACTIONS ARE REVIEWED FOR ANY POTENTIAL CONFLICTS OF INTERESTS. ANY ISSUES ARE BROUGHT TO THE ATTENTION OF THE EXECUTIVE COMMITTEE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 15</FormAndLineReferenceDesc>
        <ExplanationTxt>THE BOARD'S EXECUTIVE COMMITTEE DETERMINES COMPENSATION AND BENEFITS FOR THE PRESIDENT/CEO AFTER REVIEWING THE MOST CURRENT GUIDESTAR NONPROFIT COMPENSATION REPORT, OTHER COMPARABLE DATA, SCOPE OF RESPONSIBILITY, SIZE OF ORGANIZATION, RESPONSIBILITY AND BUDGET TO DETERMINE THE REASONABLENESS OF THE SALARY.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION C, LINE 18</FormAndLineReferenceDesc>
        <ExplanationTxt>RECENT FILINGS OF THE FORM 990 ARE AVAILABLE ONLINE AT CURETHEKIDS.ORG, GUIDESTAR, AND CHARITY NAVIGATOR.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION C, LINE 19</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE THROUGH INSPECTION AT THE ADMINISTRATIVE OFFICE IN FAIRVIEW, NC. ADDITIONALLY, THESE DOCUMENTS ARE MADE AVAILABLE TO ALL STATE GOVERNMENTS THAT REQUIRE ANNUAL FILING OF CHARITABLE ORGANIZATIONS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART XII, LINE 2C:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
  </ReturnData>
</Return>
